MGC Pharmaceuticals To Bring Cannabis To London Main Market In IPO

(Alliance News) - MGC Pharmaceuticals Ltd on Monday said it is in the final stages of listing on ...

Alliance News 1 February, 2021 | 11:17AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - MGC Pharmaceuticals Ltd on Monday said it is in the final stages of listing on the Main Market of the London Stock Exchange, seeking to raise GBP5 million as part of the process.

MGC Pharma is listed in Australia and is a Europe-based biopharmaceutical company specialising in the production and development of phytocannabinoid-derived medicines. It said its initial public offering will be one of the first on the London Main Market by a cannabis-sector company.

Proceeds from the capital raise will go towards meeting the costs for the clinical trials of ArtemiC and CannEpil, meeting registration costs for ArtemiC in new markets including Russia and the Middle East, as well as completing the construction of the group manufacturing facilities in Malta.

The capital raise is being carried out with UK institutional funds and investor clients of equity broker Turner Pope. The IPO is expected to be completed within February.

CannEpil is designed as a treatment for refractory epilepsy and ArtemiC is for the treatment of Covid-19 infected patients.

MGC said that having a dual listing in both London and Sydney will increase the company's international profile, provide access to UK capital markets and investors, and as one of the first cannabis-related firms listed, will provide investors with an opportunity to gain exposure to the sector. Its primary listing will remain on the Australian Stock Exchange.

MGC Pharma recorded revenue of AUD2.1 million, about GBP1.2 million, in 2020.

"I am delighted to announce we are moving forward with the admission of MGC Pharmaceuticals to the main market of the London Stock Exchange, which will position the company for the next phase of its growth and development. Our listing is the culmination of the last six years of hard work, positioning MGC Pharma as a leader in the emerging phytocannabinoid pharmaceutical sector," said Managing Director Roby Zomer.

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures